Vaccine Development: From Concept to Clinic
Vaccine development is a complex and time consuming process that differs from the development of conventional pharmaceuticals. Primarily, vaccines are intended for use in healthy individuals as a preventative measure, requiring a long and rigorous process of research and many years of testing and development prior to clinical trials and regulatory approval. The average time for the development of vaccines to clinical is 12 to 15 years. Vaccine Development: From Concept to Clinic is a detailed overview of the development of new vaccines, covering the entire process and addresses all classes of vaccines from a processing, development and regulatory viewpoint. Utilising successful case studies the book will provide insight to the issues scientists face when producing a vaccine, the steps involved and will serve as an ideal reference tool regarding state-of-the-art vaccine development. This book is an ideal companion for any researchers working in vaccine discovery and development or with an interest in the field.
Vaccine Development: From Concept to Clinic, The Royal Society of Chemistry, 2022.
Download citation file:
Digital access
Print format
Table of contents
-
Chapter 1: Vaccine Development: From Concept to Clinicp1-21ByA. Krishna PrasadA. Krishna PrasadSearch for other works by this author on:
-
Chapter 2: Preclinical Safety Assessment Considerations for Vaccine Developmentp22-49ByDavid W. ClarkeDavid W. ClarkeSearch for other works by this author on:
-
Chapter 3: Clinical Trials in the Development of Vaccines for Infectious Diseasesp50-90ByW. C. GruberW. C. GruberPfizer Vaccine Research and Development401 N. Middletown RoadPearl RiverNY 10965USASearch for other works by this author on:
-
Chapter 4: Clinical Trials in Immunotherapeutic Vaccine Developmentp91-111ByDemissie Alemayehu;Demissie AlemayehuPfizer Global Biometrics and Data Management, Global Product Development235 East 42nd StreetNew YorkNY 10017USA[email protected]Search for other works by this author on:Charles A. KnirschCharles A. KnirschPfizer Worldwide Research and Development235 East 42nd StreetNew YorkNY 10017USASearch for other works by this author on:
-
Chapter 5: Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs Against COVID-19p112-131ByAmy V. Paschall;Amy V. PaschallDepartment of Biochemistry, Emory Vaccine Center, Emory University School of Medicine1510 Clifton Rd. AtlantaGA 30322USA[email protected]Search for other works by this author on:Fikri Y. AvciFikri Y. AvciDepartment of Biochemistry, Emory Vaccine Center, Emory University School of Medicine1510 Clifton Rd. AtlantaGA 30322USA[email protected]Search for other works by this author on:
-
Chapter 6: High-throughput Assays for Clinical Developmentp132-161ByPeter C. GiardinaPeter C. GiardinaPfizer Inc.Pearl RiverNY 10965USASearch for other works by this author on:
-
Chapter 7: Virus-like Particle-based Vaccines: GARDASIL®p162-177ByP. Dephillips;P. DephillipsMerck & Co., Inc., MRLSumneytown PikeWest PointPA 19486USASearch for other works by this author on:D. AbrahamD. AbrahamSearch for other works by this author on:
-
Chapter 8: Cell Culture-based Influenza Vaccine Developmentp178-198ByPirada Suphaphiphat;Pirada SuphaphiphatSeqirus Inc.50 Hampshire StreetCambridgeMA 02139USASearch for other works by this author on:Yingxia WenYingxia WenSeqirus Inc.50 Hampshire StreetCambridgeMA 02139USASearch for other works by this author on:
-
Chapter 9: Conjugate Vaccines: Design and Development Considerationsp199-213ByA. Krishna PrasadA. Krishna PrasadSearch for other works by this author on:
-
Chapter 10: Vaccine Adjuvants: Mechanisms of Actionp214-236ByHarm Hogenesch;Harm HogeneschDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue UniversityWest LafayetteIN 47907USA[email protected]Search for other works by this author on:Mark T. Orr;Mark T. OrrImmuno-Oncology and Cellular Therapy Thematic Research Center, Bristol-Myers SquibbSeattleWA 98109USASearch for other works by this author on:Christopher B. FoxChristopher B. FoxInfectious Disease Research InstituteSeattleWA 98102USASearch for other works by this author on:
-
Chapter 11: Development Considerations for Final Dosage Forms: Mucosal Bacterial Vaccinesp237-261ByAmish PatelAmish PatelSearch for other works by this author on:
-
Chapter 12: Exploiting Glycans in Vaccine Designp262-272ByDustin R. Middleton;Dustin R. MiddletonDepartment of Molecular Genetics and Microbiology, Duke University School of MedicineDurhamNC 27710USASearch for other works by this author on:Fikri Y. AvciFikri Y. AvciDepartment of Biochemistry Emory Vaccine Center, Emory University School of Medicine1510 Clifton Rd. AtlantaGA 30322USA[email protected]Search for other works by this author on:
-
Chapter 13: The PATH Experience in Vaccine Development Partnerships with Manufacturers from Emerging Marketsp273-297ByMark R. Alderson;Mark R. AldersonPATH2201 Westlake AvenueSeattleWA 98121USASearch for other works by this author on:William P. Hausdorff;William P. HausdorffFaculty of Medicine, Université Libre de BruxellesBrusselsBelgiumSearch for other works by this author on:Anthony A. MarfinAnthony A. MarfinPATH2201 Westlake AvenueSeattleWA 98121USASearch for other works by this author on:
Spotlight
Advertisement
Advertisement